VCM
TRVI icon

Versant Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Versant Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-232
Closed -$2.77K – 2854
2026
Q1 		$2.77K Buy
+232
New +$2.6K ﹤0.01% 2509

Other funds holding TRVI

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
DACS
Dymon Asia Capital (Singapore) Singapore $2.39B AUM 150.5% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return

Versant Capital Management's TRVI Position: Q2 2026 in Review

Versant Capital Management sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 232 shares — an estimated $2.77K sold.

Versant Capital Management first reported a position in TRVI in Q1 2026 and held it in 1 quarter. The position peaked at $2.77K in Q1 2026. 20 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Versant Capital Management reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 232 Trevi Therapeutics shares in Q2 2026, an estimated $2.77K.
  • Versant Capital Management first reported a position in Trevi Therapeutics in Q1 2026 and held it in 1 quarter.
  • Versant Capital Management's Trevi Therapeutics position peaked at $2.77K in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.